BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11392031)

  • 1. Endometrial hyperplasia. Risks, recognition and the search for a safe hormone replacement regimen.
    de Lignieres B
    J Reprod Med; 1999 Feb; 44(2 Suppl):191-6. PubMed ID: 11392031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral micronized progesterone.
    de Lignières B
    Clin Ther; 1999 Jan; 21(1):41-60; discussion 1-2. PubMed ID: 10090424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protecting the endometrium. Opposing the hyperplasia/malignancy potential of ERT.
    Gibbons WE; Thorneycroft IH
    J Reprod Med; 1999 Feb; 44(2 Suppl):203-8. PubMed ID: 11392033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen, progestogens and cardiovascular risk.
    Stefanick ML
    J Reprod Med; 1999 Feb; 44(2 Suppl):221-6. PubMed ID: 11392036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone replacement therapy and endometrial cancer.
    Emons G; Huschmand-Nia A; Krauss T; Hinney B
    Onkologie; 2004 Apr; 27(2):207-10. PubMed ID: 15138357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oestrogens and endometrial hyperplasia.
    Thom MH; Studd JW
    Br J Hosp Med; 1980 May; 23(5):506, 508-9, 511-3. PubMed ID: 6992895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
    Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
    Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing safety and efficacy focus on endometrial protection.
    Boroditsky RS
    J Reprod Med; 2000 Mar; 45(3 Suppl):273-84. PubMed ID: 10756508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaginal bleeding patterns in women receiving hormone replacement therapy. Impact of various progestogen regimens.
    Thorneycroft IH; Gibbons WE
    J Reprod Med; 1999 Feb; 44(2 Suppl):209-14. PubMed ID: 11392034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer].
    Magnusson C; Weiderpass E
    Lakartidningen; 2001 Jan; 98(5):418-21. PubMed ID: 11229082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmenopausal hormone replacement therapy: endometrial and breast effects.
    Yeh IT
    Adv Anat Pathol; 2007 Jan; 14(1):17-24. PubMed ID: 17198307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
    Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgenic progestins amplify the breast cancer risk associated with hormone replacement therapy by boosting IGF-I activity.
    McCarty MF
    Med Hypotheses; 2001 Feb; 56(2):213-6. PubMed ID: 11425289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for hormone replacement therapy in atherosclerosis prevention.
    Wagner JD
    J Reprod Med; 2000 Mar; 45(3 Suppl):245-58. PubMed ID: 10756506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Estrogen and progestin treatment in postmenopause. Effects on the endometrium].
    Grio R; Curti A; Gobbi F; Piacentino R
    Minerva Ginecol; 1998 Dec; 50(12):553-6. PubMed ID: 10069171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone replacement therapy and risk of breast cancer: the role of progestins.
    Stahlberg C; Pedersen AT; Lynge E; Ottesen B
    Acta Obstet Gynecol Scand; 2003 Apr; 82(4):335-44. PubMed ID: 12716318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy.
    Figueroa-Casas PR; Ettinger B; Delgado E; Javkin A; Vieder C
    Menopause; 2001; 8(6):420-3. PubMed ID: 11723414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunohistochemical study of the expression of receptors to steroid hormones in endometrial hyperplastic processes].
    Lysenko ON; Ashkhab MKh; Strizhova NV; Babichenko II
    Arkh Patol; 2004; 66(2):7-10. PubMed ID: 15154374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
    Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
    Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.